Selective modulation of glucocorticoid receptor function toward development of novel antiinflammation: Lessons from a phenylpyrazolosteroid cortivazol

Modern Rheumatology

Volumn 14, Issue 5, 2004, Pages 347-355

  Tanaka, Hirotoshi ^a   Yoshikawa, Noritada ^a   Shimizu, Noriaki ^a   Morimoto, Chikao ^a  

^a UNIVERSITY OF TOKYO   (Japan)

Author keywords

Co activator; Conformation; Glucocorticoid receptor (GR); Ligand binding domain (LBD); Transcription

Indexed keywords

10 METHOXY 2,2,4 TRIMETHYLBENZOPYRAZOPYRAZOL[3,4 F]QUINOLINE; 4 (2,3 DIHYDROBENZOFURAN 7 YL) 2 HYDROXY 3,3 DIMETHYL N (4 METHYL 1 OXO 2,3 BENZOXAZIN 6 YL) 2 TRIFLUOROMETHYLBUTANAMIDE; 5 ALLYL 2,5 DIHYDRO 2,2,4 TRIMETHYL 1H 1 BENZOPYRAZOLO[3,4 F]QUINIDINE; A 276575; AL 438; ANDROGEN RECEPTOR; CELL NUCLEUS RECEPTOR; CORTIVAZOL; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; HORMONE RECEPTOR BLOCKING AGENT; HORMONE RECEPTOR STIMULATING AGENT; MINERALOCORTICOID RECEPTOR; PROGESTERONE RECEPTOR MODULATOR; RU 24858; SELECTIVE ESTROGEN RECEPTOR MODULATOR; TRANSCRIPTION FACTOR AP 1; UNCLASSIFIED DRUG; URSODEOXYCHOLIC ACID;

CARBOXY TERMINAL SEQUENCE; CUSHING SYNDROME; DNA RESPONSIVE ELEMENT; DRUG POTENCY; DRUG RECEPTOR BINDING; GLUCONEOGENESIS; GROWTH RETARDATION; HORMONE ACTION; HUMAN; MOLECULAR BIOLOGY; OSTEOPOROSIS; PRIORITY JOURNAL; PROTEIN FUNCTION; REVIEW; SKIN ATROPHY;

EID: 8444227037     PISSN: 14397595     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10165-004-0322-5     Document Type: Review

References (54)

1. Sapolsky RM, Romero LM, Munck AU. How do glucocorticoids influence stress responses? Integrating permissive, suppressive, stimulatory, and preparative actions. Endocr Rev 2000;21:55-89.
2. Reichardt HM, Tronche F, Berger S, Kellendonk C, Schutz G. New insights into glucocorticoid and mineralocorticoid signaling: lessons from gene targeting. Adv Pharmacol 2000;47:1-21.
3. Adcock IM. Glucocorticoids: New mechanisms and future agents. Curr Allergy Asthma Rep 2003;3:249-57.
4. Moreland LW, O'Dell JR. Glucocorticoids and rheumatoid arthritis: back to the future? Arthritis Rheum 2002;46:2553-63.
5. Miner JN. Designer glucocorticoids. Biochem Pharmacol 2002; 64:355-61.
6. A unified nomenclature system for the nuclear receptor superfamily. Cell 1999;97:161-3.
7. Beato M, Herrlich P, Schutz G. Steroid hormone receptors: Many actors in search of a plot. Cell 1995;83:851-7.
8. Mangelsdorf DJ, Thummel C, Beato M, Herrlich P, Schutz G, Umesono K, et al. The nuclear receptor superfamily: The second decade. Cell 1995;83:835-9.
9. De Bosscher K, Vanden Berghe W, Haegeman G. Mechanisms of anti-inflammatory action and of immunosuppression by glucocorticoids: negative interference of activated glucocorticoid receptor with transcription factors. J Neuroimmunol 2000;109:16-22.
10. McKay LI, Cidlowski JA. Molecular control of immune/inflammatory responses: Interactions between nuclear factor-kappa B and steroid receptor-signaling pathways. Endocr Rev 1999;20:435-59.
11. Tuckermann JP, Reichardt HM, Arribas R, Richter KH, Schutz G, Angel P. The DNA binding-independent function of the glucocorticoid receptor mediates repression of AP-1-dependent genes in skin. J Cell Biol 1999;147:1365-70.
12. Kauppi B, Jakob C, Farnegardh M, Yang J, Ahola H, Alarcon M, et al. The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism. J Biol Chem 2003;278:22748-54.
13. Bledsoe RK, Montana VG, Stanley TB, Delves CJ, Apolito CJ, McKee DD, et al. Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition. Cell 2002;110:93-105.
14. Berry M, Metzger D, Chambon P. Role of the two activating domains of the oestrogen receptor in the cell-type and promotercontext dependent agonistic activity of the anti-oestrogen 4-hydroxytamoxifen. EMBO J 1990;9:2811-8.
15. Kraus WL, McInerney EM, Katzenellenbogen BS. Ligand-dependent, transcriptionally productive association of the amino-and carboxyl-terminal regions of a steroid hormone nuclear receptor. Proc Natl Acad Sci USA 1995;92:12314-8.
16. Rosenfeld MG, Glass CK. Coregulator codes of transcriptional regulation by nuclear receptors. J Biol Chem 2001;276:36865-8.
17. Kadonaga JT. Regulation of RNA polymerase II transcription by sequence-specific DNA binding factors. Cell 2004;116:247-57.
18. Robyr D, Wolffe AP, Wahli W. Nuclear hormone receptor coregulators in action: Diversity for shared tasks. Mol Endocrinol 2000;14:329-47.
19. Sheppard KA, Phelps KM, Williams AJ, Thanos D, Glass CK, Rosenfeld MG, et al. Nuclear integration of glucocorticoid receptor and nuclear factor-kappaB signaling by CREB-binding protein and steroid receptor coactivator-1. J Biol Chem 1998;273:29291-4.
20. Kumar R, Lee JC, Bolen DW, Thompson EB. The conformation of the glucocorticoid receptor af1/tau1 domain induced by osmolyte binds co-regulatory proteins. J Biol Chem 2001;276: 18146-52.
21. Kumar R, Thompson EB. Transactivation functions of the N-terminal domains of nuclear hormone receptors: Protein folding and coactivator interactions. Mol Endocrinol 2003;17:1-10.
22. McKenna NJ, O'Malley BW. Combinatorial control of gene expression by nuclear receptors and coregulators. Cell 2002;108:465-74.
23. Wallberg AE, Neely KE, Hassan AH, Gustafsson JA, Workman JL, Wright AP. Recruitment of the SWI-SNF chromatin remodeling complex as a mechanism of gene activation by the glucocorticoid receptor tau1 activation domain. Mol Cell Biol 2000;20:2004-13.
24. 2-terminal interaction with the ligand binding domain of the androgen receptor. J Biol Chem 2000;275: 22986-94.
25. Tetel MJ, Giangrande PH, Leonhardt SA, McDonnell DP, Edwards DP. Hormone-dependent interaction between the amino- and carboxyl-terminal domains of progesterone receptor in vitro and in vivo. Mol Endocrinol 1999;13:910-24.
26. Onate SA, Boonyaratanakornkit V, Spencer TE, Tsai SY, Tsai MJ, Edwards DP, et al. The steroid receptor coactivator-1 contains multiple receptor interacting and activation domains that cooperatively enhance the activation function 1 (AF1) and AF2 domains of steroid receptors. J Biol Chem 1998;273:12101-8.
27. Gelman L, Zhou G, Fajas L, Raspe E, Fruchart JC, Auwerx J. p300 interacts with the N- and C-terminal part of PPARgamma2 in a ligand-independent and -dependent manner, respectively. J Biol Chem 1999;274:7681-8.
28. Hammer GD, Krylova I, Zhang Y, Darimont BD, Simpson K, Weigel NL, et al. Phosphorylation of the nuclear receptor SF-1 modulates cofactor recruitment: Integration of hormone signaling in reproduction and stress. Mol Cell 1999;3:521-6.
29. Hittelman AB, Burakov D, Iniguez-Lluhi JA, Freedman LP, Garabedian MJ. Differential regulation of glucocorticoid receptor transcriptional activation via AF-1-associated proteins. Embo J 1999;18:5380-8.
30. Geistlinger TR, McReynolds AC, Guy RK. Ligand-selective inhibition of the interaction of steroid receptor coactivators and estrogen receptor isoforms. Chem Biol 2004;11:273-81.
31. 3H]cortivazol: A unique high affinity ligand for the glucocorticoid receptor. Endocrinology 1998;117:1355-62.
32. Yoshikawa N, Makino Y, Okamoto K, Morimoto C, Makino I, Tanaka H. Distinct interaction of cortivazol with the ligand binding domain confers glucocorticoid receptor specificity: Cortivazol is a specific ligand for the glucocorticoid receptor. J Biol Chem 2002; 277:5529-40.
33. Steelman SL, Morgan ER, Glitzer MS. Heterocyclic corticosteroids. I. Biological properties of the 6,16-dimethyl-4,6-pregnadiene-11,17,21-triol-20-one(3,2c -2′-phenylpyrazole-21-acetate and its 21-desoxy derivative. Steroids 1971;18:129-39.
34. Simons SS Jr, Thompson EB, Johnson DF. Anti-inflammatory pyrazolo-steroids: Potent glucocorticoids containing bulky A-ring substituents and no C3-carbonyl. Biochem Biophys Res Commun 1979;86:792-800.
35. Farnegardh M, Bonn T, Sun S, Ljunggren J, Ahola H, Wilhelmsson A, et al. The three dimensional structure of the liver X receptor beta reveals a flexible ligand binding pocket that can accommodate fundamentally different ligands. J Biol Chem 2003;278;38821-8.
36. Geller DS, Farhi A, Pinkerton N, Fradley M, Moritz M, Spitzer A, et al. Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy. Science 2000;289:119-23.
37. Williams SP, Sigler PB. Atomic structure of progesterone complexed with its receptor. Nature 1998;393:392-6.
38. Zhang S, Liang X, Danielsen M. Role of the C terminus of the glucocorticoid receptor in hormone binding and agonist/antagonist discrimination. Mol Endocrinol 1996;10:24-34.
39. Ford J, McEwan IJ, Wright AP, Gustafsson JA. Involvement of the transcription factor IID protein complex in gene activation by the N-terminal transactivation domain of the glucocorticoid receptor in vitro. Mol Endocrinol 1997;11:1467-75.
40. Wardell SE, Boonyaratanakornkit V, Adelman JS, Aronheim A, Edwards DP. Jun dimerization protein 2 functions as a progesterone receptor N-terminal domain coactivator. Mol Cell Biol 2002;22:5451-66.
41. Rogerson FM, Brennan FE, Fuller PJ. Mineralocorticoid receptor binding, structure and function. Mol Cell Endocrinol 2004;217: 203-12.
42. Baxter JD, Funder JW, Apriletti JW, Webb P. Towards selectively modulating mineralocorticoid receptor function: Lessons from other systems. Mol Cell Endocrinol 2004;217:151-65.
43. Galigniana MD, Piwien Pilipuk G. Activation of the ligand-mineralocorticoid receptor functional unit by ancient, classical, and novel ligands: Structure-activity relationship. Vitam Horm 2004; 69:31-68.
44. Kitagawa H, Yanagisawa J, Fuse H, Ogawa S, Yogiashi Y, Okuno A, et al. Ligand-selective potentiation of rat mineralocorticoid receptor activation function 1 by a CBP-containing histone acetyltransferase complex. Mol Cell Biol 2002;22:3698-706.
45. Ghali SA, Gottlieb B, Lumbroso R, Beitel LK, Elhaji Y, Wu J, et al. The use of androgen receptor amino/carboxyl-terminal interaction assays to investigate androgen receptor gene mutations in subjects with varying degrees of androgen insensitivity. J Clin Endocrinol Metab 2003;88:2185-93.
46. Teutsch G, Costerousse G, Deraedt R, Benzoni J, Fortin M, Philibert D. 17α-Alkynyl-11β,17-dihydroxyandrostane derivatives: a new class of potent glucocorticoids. Steroids 1981;38:651-65.
47. Ali A, Thompson CF, Balkovec JM, Graham DW, Hammond ML, Quraishi N, et al. Novel N-arylpyrazolo[3,2-c]-based ligands for the glucocorticoid receptor: Receptor binding and in vivo activity. J Med Chem 2004;47:2441-52.
48. Vayssiere BM, Dupont S, Choquart A, Petit F, Garcia T, Marchandeau C, et al. Synthetic glucocorticoids that dissociate transactivation and AP-1 transrepression exhibit antiinflammatory activity in vivo. Mol Endocrinol 1997;11:1245-55.
49. Miura, T, Ouchida R, Yoshikawa N, Okamoto K, Makino Y, Nakamura T, et al. Functional modulation of the glucocorticoid receptor and suppression of NF-κB-dependent transcription by ursodeoxycholic acid. J Biol Chem 2001;276:47371-8.
50. Lin CW, Nakane M, Stashko M, Falls D, Kuk J, Miller L, et al. trans-Activation and represion properties of the novel nonsteroid glucocorticoid receptor ligand 2,5-dihydro-9-hydroxy-10-methoxy-2, 2-4-trimethyl-5-(1-methylcyclohexen-3-y1)-1H-[1]benzopyrano [3,4-f]quinoline (A276575) and its four stereoisomers. Mol Pharmacol 2002;62:297-303.
51. Coghlan MJ, Jacobson PB, Lane B, Nakane M, Lin C-W, Elmore SW, et al. A novel antiinflammatory maintains glucocorticoid efficacy with reduced side effects. Mol Endocrinol 2003;17:860-9.
52. Kym PR, Kort ME, Coghlan MJ, Moore JL, Tang R, Ratajczyk JD, et al. Nonsteroidal selective glucocorticoid modulators: the effect of C-10 substitution on receptor selectivity and functional potency of 5-allyl-2,5-dihydro-2,2,4-trimethyl-1H-[1]benzopyrano [3,4-f]quinolines. J Med Chem 2003;46:1016-30.
53. Schacke H, Schottelius A, Docke WD, Strehlke P, Jaroch S, Schmees N, et al. Dissociation of transactivaiton from transrepression by a selective glucocorticoid receptor agonist leads to separatoin of therapeutic effects from side effects. Proc Natl Acad Sci USA 2004;101:227-32.
54. Elmore SW, Pratt JK, Coghlan, MJ, Mao Y, Green BE, Anderson DD, et al. Differentiation of in vitro transcriptional repression and activation profiles of selective glucocorticoid modulators. Bioorg Med Chem Lett 2004;14:1721-7.